罕见心血管疾病诊疗进展

张抒扬; 田庄; 张舒媛; 王泽源

doi:10.12376/j.issn.2097-0501.2023.01.001

罕见心血管疾病诊疗进展

doi: 10.12376/j.issn.2097-0501.2023.01.001

张抒扬^{1, 2, ,},
田庄^{1, 2, 3},
张舒媛^{1, 2, 4},
王泽源^{1, 2}

1.
中国医学科学院北京协和医院心内科，北京 100730
2.
中国医学科学院北京协和医院疑难重症及罕见病国家重点实验室，北京 100730
3.
中国医学科学院北京协和医院国际医疗部，北京 100730
4.
中国医学科学院北京协和医院医学科学研究中心，北京 100730

基金项目:

中国医学科学院医学与健康科技创新工程 2021-I2M-1-003

详细信息

通信作者:
张抒扬，E-mail：shuyangzhang103@163.com

中图分类号: R-1; R54
计量
- 文章访问数: 86
- HTML全文浏览量: 11
- PDF下载量: 15
- 被引次数: 0
出版历程
- 收稿日期: 2023-01-04
- 修回日期: 2023-01-12

Advances in the Diagnosis and Treatment of Rare Cardiovascular Diseases

ZHANG Shuyang^{1, 2
, ,},
TIAN Zhuang^{1, 2, 3},
ZHANG Shuyuan^{1, 2, 4},
WANG Zeyuan^{1, 2}

1.
Department of Cardiology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
2.
State Key Laboratory of Complex Severe and Rare Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
3.
Department of International Medical Services, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
4.
Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funding:

Chinese Academy of Medical Sciences(CAMS) Innovation Fund for Medical Sciences 2021-I2M-1-003

More Information

Corresponding author: ZHANG Shuyang, E-mail: shuyangzhang103@163.com

摘要

摘要: 罕见心血管疾病发病早、死亡率较高，患者长期面临诊断难和治疗率低的困境，因此亟需提升罕见病诊疗水平，加速罕见心血管疾病药物的筛选和研发。近年来，随着新技术和基础研究的迅猛发展，罕见心血管疾病诊疗有了突破性进展。本文总结罕见心血管疾病诊疗的相关研究进展，并对未来研究方向做出展望。
- 罕见病 /
- 心血管疾病 /
- 诊断 /
- 治疗
Abstract: The onset of rare cardiovascular diseases is early and the mortality is high. The patients of the disease face a long time of hardship in diagnosis and a low treatment rate. As a result, it is urgent to improve the diagnosis and treatment level of rare diseases and to accelerate the selection and R&D of drugs of rare cardiovascular diseases. In recent years, with the rapid development of new technology and basic research, the diagnosis and treatment of rare cardiovascular diseases have made breakthroughs. The article summarizes the research progress in diagnosis and treatment of rare cardiovascular diseases and looks into the future of the research.
- rare diseases /
- cardiovascular diseases /
- diagnosis /
- treatment
注释:

作者贡献：张抒扬负责提出修订意见，审校论文；田庄提出选题思路，并负责审校论文；张舒媛负责论文撰写及修订；王泽源负责查阅文献。

利益冲突：所有作者均声明不存在利益冲突。

HTML全文

参考文献(25)

[1]	国家卫生健康委员会, 科学技术部, 工业和信息化部, 等. 关于公布第一批罕见病目录的通知(国卫医发〔2018〕10号)[EB/OL]. (2018-06-08)[2022-11-29]. http://www.gov.cn/gongbao/content/2018/content_5338244.htm.
[2]	Zhou M, Wang H, Zeng X et al. Mortality, morbidity, and risk factors in China and its provinces, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. doi: 10.1016/S0140-6736(19)30427-1
[3]	中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志, 2022, 37(6): 553-578. doi: 10.3969/j.issn.1000-3614.2022.06.001
[4]	国家卫生健康委办公厅. 关于印发罕见病诊疗指南(2019年版)的通知(国卫办医函〔2019〕198号)[EB/OL]. (2019-02-28)[2022-12-07]. http://www.gov.cn/fuwu/2019-02/28/content_5369203.htm.
[5]	Turro E, Astle WJ, Megy K, et al. Whole-genome sequencing of patients with rare diseases in a national health system[J]. Nature, 2020, 583(7814): 96-102. doi: 10.1038/s41586-020-2434-2
[6]	Mizusawa Y, Horie M, Wilde AA. Genetic and clinical advances in congenital long QT syndrome[J]. Circ J, 2014, 78(12): 2827-2833. doi: 10.1253/circj.CJ-14-0905
[7]	Priest JR, Ceresnak SR, Dewey FE, et al. Molecular diagnosis of long QT syndrome at 10 days of life by rapid whole genome sequencing[J]. Heart Rhythm, 2014, 11(10): 1707-1713. doi: 10.1016/j.hrthm.2014.06.030
[8]	Reichart D, Lindberg EL, Maatz H, et al. Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies[J]. Science, 2022, 377(6606): eabo1984. doi: 10.1126/science.abo1984
[9]	McAfee Q, Chen CY, Yang Y, et al. Truncated titin proteins in dilated cardiomyopathy[J]. Sci Transl Med, 2021, 13(618): eabd7287. doi: 10.1126/scitranslmed.abd7287
[10]	Liu H, Jin Y, Tian R, et al. A comprehensive analysis of genomics and metagenomics in a heterozygote familial hypercholesterolemia family[J]. Front Cell Infect Microbiol, 2021, 11: 605954. doi: 10.3389/fcimb.2021.605954
[11]	Chen L, Song J, Chen X, et al. A novel genotype-based clinicopathology classification of arrhythmogenic cardiomyopathy provides novel insights into disease progression[J]. Eur Heart J, 2019, 40(21): 1690-1703. doi: 10.1093/eurheartj/ehz172
[12]	Goto S, Mahara K, Beuussink-Nelson L, et al. Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms[J]. Nat Commun, 2021, 12(1): 2726. doi: 10.1038/s41467-021-22877-8
[13]	Kwon JM, Kim KH, Medina-Inojosa J, et al. Artificial intelligence for early prediction of pulmonary hypertension using electrocardiography[J]. J Heart Lung Transplant, 2020, 39(8): 805-814. doi: 10.1016/j.healun.2020.04.009
[14]	Ko WY, Siontis KC, Attia ZI, et al. Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram[J]. J Am Coll Cardiol, 2020, 75(7): 722-733. doi: 10.1016/j.jacc.2019.12.030
[15]	Shrivastava S, Cohen-Shelly M, Attia ZI, et al. Artificial intelligence-enabled electrocardiography to screen patients with dilated cardiomyopathy[J]. Am J Cardiol, 2021, 155: 121-127. doi: 10.1016/j.amjcard.2021.06.021
[16]	Zhao Q, Wang X, Wang S, et al. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes[J]. Stem Cell Res Ther, 2017, 8(1): 54. doi: 10.1186/s13287-017-0473-x
[17]	Cerrone M, Lin X, Zhang M, et al. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a Brugada syndrome phenotype[J]. Circulation, 2014, 129(10): 1092-1103. doi: 10.1161/CIRCULATIONAHA.113.003077
[18]	Liang P, Sallam K, Wu H, et al. Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of Brugada syndrome[J]. J Am Coll Cardiol, 2016, 68(19): 2086-2096. doi: 10.1016/j.jacc.2016.07.779
[19]	Yang J, Grafton F, Ranjbarvaziri S, et al. Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy[J]. Sci Transl Med, 2022, 14(652): eabl5654. doi: 10.1126/scitranslmed.abl5654
[20]	Lewis-Israeli YR, Wasserman AH, Gabalski MA, et al. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease[J]. Nat Commun, 2021, 12(1): 5142. doi: 10.1038/s41467-021-25329-5
[21]	Bass-Stringer S, Bernardo BC, May CN, et al. Adeno-associated virus gene therapy: translational progress and future prospects in the treatment of heart failure[J]. Heart Lung Circ, 2018, 27(11): 1285-1300. doi: 10.1016/j.hlc.2018.03.005
[22]	Yu G, Chakrabarti S, Tischenko M, et al. Gene therapy targeting protein trafficking regulator MOG1 in mouse models of Brugada syndrome, arrhythmias, and mild cardiomyopathy[J]. Sci Transl Med, 2022, 14(648): eabf3136. doi: 10.1126/scitranslmed.abf3136
[23]	Heggermont WA, Papageorgiou AP, Quaegebeur A, et al. Inhibition of microRNA-146a and overexpression of its target dihydrolipoyl succinyltransferase protect against pressure overload-induced cardiac hypertrophy and dysfunction[J]. Circulation, 2017, 136(8): 747-761. doi: 10.1161/CIRCULATIONAHA.116.024171
[24]	Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloid-osis[J]. N Engl J Med, 2021, 385(6): 493-502. doi: 10.1056/NEJMoa2107454
[25]	国家药品监督管理局药品审评中心. 关于发布第一批临床急需境外新药名单的通知[EB/OL]. (2018-11-01)[2022-11-29]. https://www.cde.org.cn/main/news/viewInfoCommon/21de8acd6c395746b041b2ad93eb5c43.